DENVER -- Oral zolmitriptan was effective and well tolerated for the treatment of migraine associated with menses, Dr. Elizabeth Loder reported at the annual meeting of the American Academy of Neurology
The finding was seen in an 18-center, randomized, placebo-controlled trial involving 510 women with one to three such headaches and a history of menses-associated migraine. The study was sponsored by AstraZeneca, manufacturer of zolmitriptan (Zomig).
A favorable headache response at 2 hours after treatment was defined as a reduction from moderate or severe pain to mild or no pain, or from mild migraine to no pain. Response rates were 48% with zolmitriptan and 27% with placebo.
"Although we have a number of retrospective post hoc analyses of response to triptans in menstrually associated migraine, this is one of the few prospective studies," said Dr. Loder of Boston, who is a consultant to Astra Zeneca.
Zolmitriptan was effective in treating migraine associated with menses in women aged 18-39 years and women aged 40-55-years. The 2-hour headache response rates were 42% and 53%, respectively In women aged 40-55 years, at least one adverse event was reported by 10% on placebo and 10% on zolmitriptan. Among 18- to 39-year-olds, the figures were 13% and 18%, respectively
COPYRIGHT 2002 International Medical News Group
COPYRIGHT 2002 Gale Group